SDZ RAD, A NEW RAPAMYCIN DERIVATIVE

1997536 citationsJournal Article

Authors

W. Schüler · Novartis (Switzerland)

Richard Sedrani · Novartis (Switzerland)

Sylvain Cottens · Novartis (Switzerland)

Barbara H berlin · Novartis (Switzerland)

Manfred Schulz · Novartis (Switzerland)

Henk‐Jan Schuurman · Novartis (Switzerland)

Gerhard Zenke ·

Abstract

In conclusion, SDZ RAD is a new, orally active rapamycin-derivative that is immunosuppressive and that efficiently prevents graft rejection in rat models of allotransplantation. SDZ RAD has therefore been selected for development for use in combination with cyclosporine A to prevent acute and chronic rejection after solid organ allotransplantation.

Topics & Keywords

Bioactive Compounds and Antitumor Agents Cancer therapeutics and mechanisms Beetle Biology and Toxicology Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Transplantation

Volume 64, Issue 1, pp. 36-42

DOI: 10.1097/00007890-199707150-00008

Field-Weighted Citation Impact: 16.30